REPROCELL co-author paper with IBM showcasing a novel ML driven precision medicine strategy for drug development
8 March 2022
Glasgow UK - 25 February 2022: REPROCELL, in collaboration with researchers at IBM and the Precision Medicine Scotland Innovation Centre, have co-authored a publication aiming to improve precision medicine strategies.
Researchers noted differences in drug response between IBD patients that varied in sex, age, or IBD type. Most interestingly, the study also linked medical histories and new genetic polymorphisms to differences in Doramapimod efficacy, one of the drugs tested during the project.
"It was incredibly exciting to work with IBM on this first-of -a-kind project," said Dr David Bunton, CEO of REPROCELL Europe and chair of the Precision Medicine Scotland Innovation Centre. "We hope that this paper will help Pharma understand the value human tissue testing can bring to their precision medicine strategies".